- Home
- BIIB vs CLX Comparison
BIIB vs CLX Comparison
Compare BIIB & CLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CLX
- Stock Information
- Founded
- BIIB 1978
- CLX 1913
- Country
- BIIB United States
- CLX United States
- Employees
- BIIB 7605
- CLX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CLX Specialty Chemicals
- Sector
- BIIB Health Care
- CLX Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CLX Nasdaq
- Market Cap
- BIIB 20.6B
- CLX 18.9B
- IPO Year
- BIIB 1991
- CLX N/A
- Fundamental
- Price
- BIIB $140.60
- CLX $157.28
- Analyst Decision
- BIIB Buy
- CLX Hold
- Analyst Count
- BIIB 27
- CLX 14
- Target Price
- BIIB $220.50
- CLX $157.07
- AVG Volume (30 Days)
- BIIB 1.5M
- CLX 1.5M
- Earning Date
- BIIB 02-12-2025
- CLX 02-03-2025
- Dividend Yield
- BIIB N/A
- CLX 3.11%
- EPS Growth
- BIIB 40.28
- CLX 478.24
- EPS
- BIIB 11.18
- CLX 3.67
- Revenue
- BIIB $9,675,900,000.00
- CLX $7,165,000,000.00
- Revenue This Year
- BIIB N/A
- CLX $1.24
- Revenue Next Year
- BIIB $1.57
- CLX $1.63
- P/E Ratio
- BIIB $12.65
- CLX $42.87
- Revenue Growth
- BIIB N/A
- CLX N/A
- 52 Week Low
- BIIB $128.51
- CLX $127.60
- 52 Week High
- BIIB $238.00
- CLX $171.37
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- CLX 55.77
- Support Level
- BIIB $135.02
- CLX $146.90
- Resistance Level
- BIIB $141.69
- CLX $150.96
- Average True Range (ATR)
- BIIB 4.00
- CLX 3.30
- MACD
- BIIB 0.04
- CLX 0.84
- Stochastic Oscillator
- BIIB 59.44
- CLX 74.35
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CLX Clorox Company (The)
Since its start more than 100 years ago, Clorox has expanded to operate in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.